Page 4,817«..1020..4,8164,8174,8184,819..4,8304,840..»

DARPA developing implant to monitor brain in real time

Posted: Published on October 28th, 2013

In a bid to improve the mental health of soldiers and veterans, DARPA has launched a $70 million project to create an implant that tracks neuron activity and provides quantifiable brain data. There's a high incidence of mental illness reported among soldiers compared with the general population -- in fact, one in nine medical discharges is due to mental illness, according to US Army statistics. This is not surprising. If you ask people to see and do horrific things, it will likely impact them in pretty significant ways. DARPA is seeking to understand more about how the brain works in hopes of developing effective therapies for troops and veterans. It has announced a new $70 million project called the Systems-Based Neurotechnology for Emerging Therapies (Subnets). Subnets is inspired by Deep Brain Stimulation, or DBS, a surgical treatment that involves implanting a brain pacemaker in the patient's skull to interfere with brain activity and help with symptoms of diseases like epilepsy and Parkinson's. DARPA's device will be similar, but rather than targeting one specific symptom, it will be able to monitor and analyze data in real time and issue a specific intervention according to brain activity. "If Subnets is successful, it … Continue reading →

Posted in Brain Injury Treatment | Comments Off on DARPA developing implant to monitor brain in real time

Brain death on the decline in Canada: study

Posted: Published on October 28th, 2013

Canadians have decreased their odds of being declared brain dead over the past decade, but better survival rates after brain injuries may also be responsible for a decline in donor organs, according to a study published Monday in the Canadian Medical Association Journal. From 2002 to 2012, the proportion of brain-injured patients in southern Alberta who deteriorated to neurologic death (brain death) declined from 8.1 per cent to 4.2 per cent a 50-per-cent reduction, noted study author Dr. Andreas Kramer, a clinical assistant professor at the University of Calgary. He said the findings are consistent with reports of decreased mortality in brain-injured patients in other regions. Brain death is on the decline in Canada, he said. Neurologic death is clearly defined in Canadian guidelines, Kramer said. It is the irreversible end of all brain activity due to permanent loss of blood flow and oxygen to the brain. It is not the same as vegetative states, in which patients may have partial awareness. And it is unlike ambiguous states of consciousness detected in patients such as Hassan Rasouli, who was kept on life support after the Supreme Court of Canada ruled on Oct. 18 that doctors at Torontos Sunnybrook Hospital could … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Brain death on the decline in Canada: study

Biogen Tops Estimates On MS Drug Sales, Boosts 2013 Outlook

Posted: Published on October 28th, 2013

Global biotechnology firm Biogen Idec, Inc. (BIIB: Quote) reported Monday a profit for the third quarter that increased 22 percent from last year, reflecting strong double-digit revenue growth amid improved sales of its multiple sclerosis drugs. Both adjusted earnings per share and quarterly revenues topped analysts' expectations. The company also raised adjusted earnings and revenues growth guidance for the full-year 2013. MS treatment Tysabri had been manufactured and distributed jointly by Biogen Idec and Elan Corp. plc (ELN), but now Biogen has acquired full rights for the therapy from Elan in the second quarter and recorded 100 percent of the revenues this quarter. Meanwhile, Biogen's Tecfidera is now the leading oral multiple sclerosis therapy in the U.S. after only six months on the market, according to IMS. It is currently approved in the U.S., Canada and Australia. The Weston, Massachusetts-based company reported net income of $467.62 million or $2.05 per share for the third quarter, higher than $398.40 million or $1.67 per share in the prior-year quarter. Excluding items, adjusted net income for the quarter was $561.1 million or $2.35 per share, compared to $454.7 million or $1.91 per share in the year-ago quarter. On average, 22 analysts polled by … Continue reading →

Posted in MS Treatment | Comments Off on Biogen Tops Estimates On MS Drug Sales, Boosts 2013 Outlook

Biogen Q3 EPS Beat Led By Its MS Drug

Posted: Published on October 28th, 2013

Biogen Idec's (BIIB) stock hit a new high Monday after it beat analysts' Q3 estimates on the strength of its new multiple sclerosis drug. Still, a new note of uncertainty with the launch of its hemophilia drug kept analysts cautious. Biogen said quarterly sales rose 32% over the year-earlier quarter to $1.83 billion, beating analysts' consensus by almost $40 million. Per-share profit minus one-time items jumped 23% to $2.35. The company raised its 2013 guidance, saying full-year revenue should rise 23% to 25%, with EPS of $8.65 to $8.85 vs. $6.53 last year. But that implied Q4 EPS below the consensus forecast. The earnings beat came almost entirely on the strength of Tecfidera, the oral MS treatment that Biogen launched six months ago. Sales totaled $286 million in the quarter, some $80 million above the consensus number and also past the "whisper number," according to ISI Group analyst Mark Schoenebaum. "This is really, truly incredible," he wrote in an email to clients early Monday. Those sales more than made up for a shortfall in Tysabri, Biogen's older MS blockbuster, whose $401 million in revenue was $29 million below consensus. This was not a surprise, however, as Elan (ELN) reported its … Continue reading →

Posted in MS Treatment | Comments Off on Biogen Q3 EPS Beat Led By Its MS Drug

BioTe – Bio Identical Hormone Replacement Therapy – With Pellets ! – Video

Posted: Published on October 28th, 2013

BioTe - Bio Identical Hormone Replacement Therapy - With Pellets ! A brief rundown of the utilization of BHRT with pellets - through the leading company in the nation: BioTE. By: Frederick Brown … Continue reading →

Posted in Hormone Replacement Therapy | Comments Off on BioTe – Bio Identical Hormone Replacement Therapy – With Pellets ! – Video

Dr James Granger on Bio-Identical Hormone Replacement Therapy in Marietta, Atlanta, GA – Video

Posted: Published on October 28th, 2013

Dr James Granger on Bio-Identical Hormone Replacement Therapy in Marietta, Atlanta, GA Dr Granger talks about Bio-Identical Hormone replacement Therapy vs the pharmaceutical version and why it is so important to understand the difference. He al... By: Eric LeRiche … Continue reading →

Posted in Hormone Replacement Therapy | Comments Off on Dr James Granger on Bio-Identical Hormone Replacement Therapy in Marietta, Atlanta, GA – Video

NPS Pharma's Natpara Looks Promising

Posted: Published on October 28th, 2013

Natpara (rhPTH [1-84]) is the most interesting candidate in NPS Pharmas (NPSP) pipeline. The candidate has been developed for the treatment of hypoparathyroidism. Hypoparathyroidism refers to a rare endocrine disorder which results in the human body producing inadequate levels of parathyroid hormone. NPS Pharma made a significant move in its attempt to bring Natpara, a replacement therapy, to the market by submitting a Biologic License Application (:BLA) to the U.S. Food and Drug Administration (:FDA). Approval of Natpara by the FDA for the hypoparathyroidism would be highly welcomed by hypoparathyroidism patients since the disease currently does not nave any FDA approved replacement therapy. Patients suffering from the disorder are currently treated with large doses of calcium supplementation and active vitamin D therapy. This helps to raise the levels of calcium in the blood while bringing down the severity of symptoms. However, this type of therapy has attendant risks like calcifications in the kidneys, arteries or brain. Apart from Natpara, NPS Pharmas pipeline includes early-stage candidates like NPSP795. The candidate, a calcilytic compound, is being developed to treat rare deficiencies involving increased calcium receptor activity. Gattex is NPS Pharmas sole marketed product. NPS Pharma launched Gattex in the U.S. in Feb … Continue reading →

Posted in Hormone Replacement Therapy | Comments Off on NPS Pharma's Natpara Looks Promising

'Sex drive slows' after stem cell transplantation

Posted: Published on October 28th, 2013

Current ratings for: 'Sex drive slows' after stem cell transplantation Ratings require JavaScript to be enabled. New research suggests that complications and preparative procedures linked to stem cell transplantation may lead to sexual dysfunction in both men and women. This is according to a study published in the journal Blood. Researchers from the City of Hope Cancer Research Hospital in Duarte, California, say that graft-versus-host disease (GVHD) - a complication that can arise after stem cell transplantation (SCT) when donor cells attack recipient cells - could be a cause of diminished sexual health. Furthermore, they found a link between diminished sexual health in men and total body radiation - a preparation treatment administered prior to the SCT procedure. Stem cell transplantation is a commonly used and effective form of treatment for those suffering from blood cancers, such as leukemia, lymphoma and myeloma. The procedure involves taking stem cells either from a patient's own blood or bone marrow, or a matched donor, and replacing the patient's damaged cells with healthy cells. The researchers note that previous studies have indicated that after this procedure, while a person may physically recover, their sexual health may be slower in returning to normal. To look … Continue reading →

Posted in Stem Cell Research | Comments Off on 'Sex drive slows' after stem cell transplantation

BioTime Organizes New ESI BIO Division to Develop, Manufacture and Market the Company’s Cell-Based Research Products

Posted: Published on October 28th, 2013

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX) today announced changes to the organization and management of its research products business. The research products business will be consolidated into a new ESI BIO Division which shall be BioTimes primary developer, manufacturer and distributor for its growing portfolio of stem-cell-based research products. Jeffrey Janus, BioTimes Vice President of Sales and Marketing, will lead ESI BIO and has also been appointed as the CEO of BioTimes Singapore-based subsidiary ES Cell International Pte Ltd. (ESI Singapore) which will be a part of the ESI BIO Division. Mr. Janus has over 30 years of experience in the cell-based biotechnology industry, serving in various executive and board level positions. ESI BIO will manufacture and market the ESI human embryonic stem (hES) cell lines developed by ESI Singapore, PureStem human embryonic progenitors, HyStem hyaluronan-based hydrogels, and kits for stem cell differentiation and reprogramming. ESI BIO also plans to develop additional new PureStem human embryonic progenitors and HyStem products, and will work with BioTimes LifeMap Sciences, Inc. subsidiary to develop and market a new database product. LifeMap Sciences will continue to use its BioReagents website to market BioTimes PureStem progenitor cells and reagents and the ESI hES … Continue reading →

Posted in Stem Cell Research | Comments Off on BioTime Organizes New ESI BIO Division to Develop, Manufacture and Market the Company’s Cell-Based Research Products

Study finds new genetic error in some lung cancers

Posted: Published on October 28th, 2013

Oct. 27, 2013 A fine-grained scan of DNA in lung cancer cells has revealed a gene fusion -- a forced merger of two normally separate genes -- that spurs the cells to divide rapidly, scientists at Dana-Farber Cancer Institute and the University of Colorado Cancer Center report in a new paper in the journal Nature Medicine. Treating the cells with a compound that blocks a protein encoded by one of those genes -- NTRK1 - caused the cells to die. The finding suggests that the fusion of NTRK1 to other genes fuels the growth of some lung adenocarcinomas (a form of non-small cell lung cancer), and that drugs that target NTRK1's protein product could be effective in patients whose lung tumors harbor such fusions. "Treatment with targeted therapies is now superior to standard chemotherapy for many patients with lung cancers that harbor genetic changes including those with fusions involving the gene ALK," says Pasi A. Jnne, MD, PhD, of Dana-Farber, the senior co-author of the paper with Robert C. Doebele, MD, PhD, of CU Cancer Center. "We know of several other genes that are fused in lung cancer and that offer attractive targets for new therapies. Our discovery places lung … Continue reading →

Comments Off on Study finds new genetic error in some lung cancers

Page 4,817«..1020..4,8164,8174,8184,819..4,8304,840..»